Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How

J.J.B.C. van Beers*, J.G.M.C. Damoiseaux

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

1 Citation (Web of Science)

Abstract

Over the years, a wide variety of therapeutic antibodies has been successfully introduced in the auto-immunology clinic, and many more are on the way. Many of these treatments address either a pathogenic circulating molecule or a cell-bound molecule. Whereas addressing the former target results in neutralization of the soluble factor and binding to the latter target either inhibits cellular function or induces selective cell death. If this targeted molecule or cell is part of the immune system, this therapy evokes a state of immunodeficiency with infections as a possible consequence. Therefore, immune monitoring is needed to prevent such adverse side effects of immunotherapy. In this paper, different immunotherapies used in Sjogren's syndrome, as well as different approaches to monitoring the immune system, are discussed.
Original languageEnglish
Article number116
Number of pages13
JournalBiomolecules
Volume11
Issue number1
DOIs
Publication statusPublished - 1 Jan 2021

Keywords

  • Sj&#246
  • biologics
  • gren&#8217
  • immune monitoring
  • s disease
  • s syndrome
  • sj&#246
  • RHEUMATOID-ARTHRITIS
  • CONTROLLED-TRIAL
  • B-CELL DEPLETION
  • CLASSIFICATION
  • PRIMARY IMMUNODEFICIENCIES
  • MONOCLONAL-ANTIBODY
  • PATHOPHYSIOLOGY
  • ABATACEPT TREATMENT
  • RITUXIMAB
  • DOUBLE-BLIND

Cite this